Summary
Purpose: To determine the response rate of patients withrefractory/relapsed non-Hodgkin's lymphoma to treatment with elsamitrucin and to further characterize the toxic effects of elsamitrucin in this group of patients.
Patients and methods: Eligibility required pathologically verified relapsed or refractory non-Hodgkin's lymphoma with no more than two prior chemotherapy regimens for patients with tumors classified by the International Working Formulation (IWF) as A-C and no more than one prior chemotherapy for those with IWF grades D-G. Patients were entered with either normal or impaired bone marrow function, but normal liver function tests were required unless clearly related to lymphomatous involvement of the liver. Elsamitrucin 25 mg/m2 was administered intravenously over 5–10 minutes weekly.
Results: Thirty-one patients entered the study and were treated for a median of six weeks (range 1–42). All patients were évaluable for toxicity and 30 for response. Mild nausea and/or vomiting and asthenia were the most frequently reported adverse events. Four (13%, 95% CI 4.4–31.6%) partial responses were seen along with two (7%) minor responses while 9 (30%) patients had stable disease.
Conclusion: Elsamitrucin showed modest activity in patients with relapsed or refractory non-Hodgkin's lymphoma. Toxicity was relatively mild, consisted mainly of asthenia, nausea and vomiting and did not include myelosuppression. The activity of elsamitrucin in this group of patients and its lack of myelosuppression suggest utility in this disease especially when combined with other proven agents.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Konishi M, Sugawara K, Kofu F, Nishiyama Y, Tomita K, Miyaki T, Kawaguchi H: Elsamicins, new antitumor antibiotics related to chartreusin. I. Production, isolation, characterization and antitumor activity. J Antibiot (Tokyo) 29:784–791, 1986
Schacter LP, Yovan N: Bristol-Myers Squibb Investigator's brochure: Elsamitrucin. Bristol-Myers Squibb, Evansville, IN, 1992
Schurig JE, Bradner WT, Basler GA, Rose WC: Experimental antitumor activity of BMY-28090, a new antitumor antibiotic. Invest New Drugs 7:173–178, 1989
Tanis BC, Vermotken JB, ten Bokkel Huinink WW, vd Vijgh WJF, Klein I, McDaniel C, Pinedo HM: Phase I study of elsamicin (BMY-28090). Proc Am Soc Clin Onc 9:71, 1990
Raber MN, Newman RA, Newman BM, Gaver RC, Schacter LP: Phase I trial and clinical pharmacology of elsamitrucin. Cancer Res 52:1406–1410, 1992
LaCreta FP, Langer C, Walczak J, Tinsley P, Schacter L, Comis RL, Ozols RF, O'Dwyer PJ: Phase I/pharmacokinetic study of elsamitrucin (BMY-28090, NSC 369327) in patients with advanced cancer. Proc Am Soc Clin Onc 9:72, 1990
Wanders J, Dombemowsky P, Verweij J, Cerny T, Piccart M, ten Bokkel Huinink WW, Calabresi F, Pavlidis N, Franklin H, Winograd B: Phase II studies of elsamitrucin in four different tumor types. Ann Oncol 3(suppl 5):47, 1992
Verweij J, Wanders J, Neilsen AL, Pavlidis N, Calabresi F, ten Bokkel Huinink WW, Bruntsch U, Piccart M, Franklin H, Kaye SB: Phase II studies of elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer, and ovarian cancer. Ann Oncol 5:375–376, 1994
Goss G, Letendre F, Stewart D, Shepherd F, Schacter L, Hoogendoorn P, Eisenhauer E: Phase II study of elsamitrucin in non-small cell lung cancer. Invest New Drugs 14:315–317, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Allen, S.L., Schacter, L.P., Lichtman, S.M. et al. Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma. Invest New Drugs 14, 213–217 (1996). https://doi.org/10.1007/BF00210793
Issue Date:
DOI: https://doi.org/10.1007/BF00210793